Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Research Article
Growing Cardiovascular and Metabolic Diseases in the Developing Countries: Is there a Role for Small Dense LDL Particles as an Inclusion Criteria for Individuals at Risk for the Metabolic Syndrome?
Anjali Arora1, Qamar A Khan2, Vrinda Arora3, Nitika Setia3 and Bobby V Khan2*
1Hyperlipidemia Prevention Clinic, Sir Ganga Ram Hospital, New Delhi, India
2Atlanta Vascular Research Foundation, Saint Joseph’s Translational Research Institute, Atlanta, Georgia, USA
3Molecular Genetics Laboratory, Center for Medical Genetics, Sir Ganga Ram Hospital, New Delhi, India
- *Corresponding Author:
- Dr. Bobby V Khan
Atlanta Vascular Research Foundation
5673 Peachtree Dunwoody Road, Suite 440
Atlanta, Georgia 30342, USA
E-mail: bobby.khan@atlantaclinicalresearch.com
Received date: May 20, 2013; Accepted date: October 08, 2013; Published date: October 10, 2013
Citation: Arora A, Khan QA, Arora V, Setia N, Khan BV (2013) Growing Cardiovascular and Metabolic Diseases in the Developing Countries: Is there a Role for Small Dense LDL Particles as an Inclusion Criteria for Individuals at Risk for the Metabolic Syndrome? J Community Med Health Educ 3:243. doi:10.4172/2161-0711.1000243
Copyright: © 2013 Arora A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
The prevalence of the metabolic syndrome is significant in nations with developed economies and is growing in countries with rapidly growing economies. The reasons for this are complex but include increased availability to cheaper (and less nutritious) food and increased mechanization. This results in reduced physical activity and an increase in total body fat and weight. Current inclusion criteria for the metabolic syndrome include parameters of obesity, elevated blood glucose, elevated triglycerides, and low HDL cholesterol. However, with the increased information regarding LDL (and specifically the small dense LDL particle) as a major risk factor for cardiovascular disease, no present consideration for LDL cholesterol as inclusion criteria for the metabolic syndrome is made. This article explores the role of LDL cholesterol as a cause and effect of complications with the metabolic syndrome in patients of these countries that are developing cardiovascular and metabolic diseases at an accelerated rate. Furthermore, as measurement of small dense LDL and apoprotein components becomes more widely available and cost effective, it may be that evaluation of these parameters and markers will assist the clinician and high-risk patient in the management and treatment of conditions that are associated with the metabolic syndrome.
